Boston Scientific
Market Cap
US$53.6b
Last Updated
2019/10/15 23:32 UTC
Data Sources
Company Financials +
Executive Summary
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
Snowflake
Fundamentals
Solid track record with high growth potential.
Similar Companies
Share Price & News
How has Boston Scientific's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.6%
BSX
3.2%
US Medical Equipment
3.4%
US Market
1 Year Return
0.9%
BSX
10.0%
US Medical Equipment
5.4%
US Market
Return vs Industry: BSX underperformed the US Medical Equipment industry which returned 10% over the past year.
Return vs Market: BSX underperformed the US Market which returned 5.4% over the past year.
Shareholder returns
| BSX | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.6% | 3.2% | 3.4% |
| 30 Day | -8.0% | -1.8% | -1.0% |
| 90 Day | -8.9% | -0.4% | -0.4% |
| 1 Year | 0.9%0.9% | 10.9%10.0% | 7.7%5.4% |
| 3 Year | 66.3%66.3% | 69.9%64.8% | 46.2%36.8% |
| 5 Year | 219.7%219.7% | 128.2%102.9% | 65.6%47.5% |
Price Volatility Vs. Market
How volatile is Boston Scientific's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is Boston Scientific Corporation (NYSE:BSX) Better Than Average At Deploying Capital?3 weeks ago | Simply Wall St
Here's What Boston Scientific Corporation's (NYSE:BSX) P/E Ratio Is Telling Us1 month ago | Simply Wall St
Is Boston Scientific Corporation (NYSE:BSX) Overpaying Its CEO?Valuation
Is Boston Scientific undervalued compared to its fair value and its price relative to the market?
1.3%
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: BSX ($38.46) is trading below our estimate of fair value ($38.99)
Significantly Undervalued: BSX is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: BSX is good value based on its PE Ratio (38.2x) compared to the Medical Equipment industry average (40.6x).
PE vs Market: BSX is poor value based on its PE Ratio (38.2x) compared to the US market (17.7x).
Price to Earnings Growth Ratio
Low PEG Ratio: BSX is poor value based on its PEG Ratio (1.5x)
Price to Book Ratio
PB vs Industry: BSX is overvalued based on its PB Ratio (5.7x) compared to the US Medical Equipment industry average (3.6x).
Next Steps
Future Growth
How is Boston Scientific forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?
24.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BSX's forecast earnings growth (24.9% per year) is above the savings rate (2.7%).
Earnings vs Market: BSX's earnings (24.9% per year) are forecast to grow faster than the US market (14.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BSX's revenue (8.4% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: BSX's revenue (8.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: BSX's Return on Equity is forecast to be high in 3 years time (25.1%)
Next Steps
Past Performance
How has Boston Scientific performed over the past 5 years?
59.5%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: BSX's earnings have grown significantly by 59.5% per year over the past 5 years.
Accelerating Growth: BSX's earnings growth over the past year (167.9%) exceeds its 5-year average (59.5% per year).
Earnings vs Industry: BSX earnings growth over the past year (167.9%) exceeded the Medical Equipment industry 28.2%.
Return on Equity
High ROE: BSX's Return on Equity (14.8%) is considered low.
Return on Assets
ROA vs Industry: BSX has a higher Return on Assets than the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: BSX has improved its Return on Capital Employed over the past 3 years.
Next Steps
Financial Health
How is Boston Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: BSX's short term assets ($6.3B) exceeds its short term liabilities ($4.9B)
Long Term Liabilities: BSX's short term assets (6.3B) do not cover its long term liabilities (10.0B)
Debt to Equity History and Analysis
Debt Level: BSX's debt to equity ratio (101.2%) is considered high
Reducing Debt: BSX's debt to equity ratio has increased from 65% to 101.2% over the past 5 years.
Debt Coverage: BSX's debt is not well covered by operating cash flow (12.2%).
Interest Coverage: BSX's interest payments on its debt are well covered by EBIT (5.9x coverage).
Balance Sheet
Inventory Level: BSX has a low level of unsold assets or inventory.
Debt Coverage by Assets: BSX's debt is not covered by short term assets (assets are 0.7x debt).
Next Steps
Dividend
What is Boston Scientific's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate BSX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BSX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if BSX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BSX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BSX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Boston Scientific's salary, the management and board of directors tenure and is there insider trading?
5.8yrs
Average management tenure
CEO
Mike Mahoney (54yo)
6.9yrs
Tenure
US$13,970,901
Compensation
Mr. Michael F. Mahoney, also known as Mike, has been Chairman of Boston Scientific Corporation since May 3, 2016, its Chief Executive Officer since November 1, 2012 and has been its President since October ...
CEO Compensation Analysis
Compensation vs. Market: Mike's total compensation ($USD13.97M) is about average for companies of similar size in the US market ($USD11.18M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Management Age and Tenure
5.8yrs
Average Tenure
53.5yo
Average Age
Experienced Management: BSX's management team is seasoned and experienced (5.8 years average tenure).
Board Age and Tenure
4.4yrs
Average Tenure
62yo
Average Age
Experienced Board: BSX's board of directors are considered experienced (4.4 years average tenure).
Insider Trading
Insider Buying: BSX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Shares | 2,455 |
| Max Price | US$41.98 |
| Entity | Individual |
| Shares | 6,000 |
| Max Price | US$42.79 |
| Entity | Individual |
| Shares | 22,047 |
| Max Price | US$38.03 |
| Entity | Individual |
| Role | Chief Information Officer Senior VP & Chief Information Officer |
| Shares | 7,803 |
| Max Price | US$38.42 |
| Entity | Individual |
| Shares | 11,980 |
| Max Price | US$39.94 |
| Entity | Individual |
| Shares | 15,298 |
| Max Price | US$36.74 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 6,143 |
| Max Price | US$37.13 |
| Entity | Individual |
| Shares | 4,000 |
| Max Price | US$38.50 |
| Entity | Individual |
| Shares | 1,500 |
| Max Price | US$36.64 |
Ownership Breakdown
Management Team
Joe Fitzgerald (55yo)
Executive VP & President of Rhythm Management
- Tenure: 9.7yrs
- Compensation: US$4.04m
Dan Brennan (53yo)
Executive VP & CFO
- Tenure: 5.8yrs
- Compensation: US$3.67m
Susie Lisa
Vice President of Investor Relations
- Tenure: 5.8yrs
Mike Mahoney (54yo)
Chairman
- Tenure: 6.9yrs
- Compensation: US$13.97m
Dave Pierce (55yo)
Executive VP & President of MedSurg
- Tenure: 8.8yrs
- Compensation: US$2.73m
Kevin Ballinger (46yo)
Executive VP & President of Interventional Cardiology
- Tenure: 6.8yrs
- Compensation: US$2.84m
Ed Mackey (56yo)
Executive Vice President of Operations
- Tenure: 4.7yrs
- Compensation: US$3.82m
Desiree Ralls-Morrison (52yo)
Senior VP
- Tenure: 1.9yrs
Jodi Eddy (46yo)
Senior VP & Chief Information Officer
- Tenure: 3.8yrs
Jonathan Monson
VP, Global Controller & Chief Accounting Officer
- Tenure: 0.3yrs
Board Members
Edward Ludwig (68yo)
Lead Independent Director
- Tenure: 3.4yrs
- Compensation: US$340.21k
Donna James (62yo)
Independent Director
- Tenure: 4.3yrs
- Compensation: US$309.98k
Steve MacMillan (55yo)
Independent Director
- Tenure: 4.5yrs
- Compensation: US$294.98k
Dave Roux (62yo)
Independent Director
- Tenure: 5.8yrs
- Compensation: US$315.51k
Ellen Zane (67yo)
Independent Director
- Tenure: 3.5yrs
- Compensation: US$294.98k
Yoshiaki Fujimori (68yo)
Independent Director
- Tenure: 3.3yrs
- Compensation: US$294.98k
Charles Dockendorff (65yo)
Independent Director
- Tenure: 4.5yrs
- Compensation: US$318.31k
Nelda Connors (53yo)
Independent Director
- Tenure: 9.8yrs
- Compensation: US$297.48k
John Sununu (54yo)
Independent Director
- Tenure: 10.5yrs
- Compensation: US$315.16k
Mike Mahoney (54yo)
Chairman
- Tenure: 6.9yrs
- Compensation: US$13.97m
Company Information
Boston Scientific Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Boston Scientific Corporation
- Ticker: BSX
- Exchange: NYSE
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$53.574b
- Shares outstanding: 1.39b
- Website: https://www.bostonscientific.com
Number of Employees
Location
- Boston Scientific Corporation
- 300 Boston Scientific Way
- Marlborough
- Massachusetts
- 1752
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BSX | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | May 1992 |
| BSX | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 1992 |
| BSX * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | May 1992 |
| 0HOY | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 1992 |
| BSXC | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | May 1992 |
Biography
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Ne ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/15 23:32 |
| End of Day Share Price | 2019/10/15 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.